First Brands Group debt targeted by Apollo Global Management - report
Investing.com - RBC Capital has raised its price target on HCA Healthcare Inc (NYSE:HCA) to $449.00 from $404.00 while maintaining an Outperform rating on the stock. The healthcare provider’s stock has demonstrated strong momentum with a 40.78% year-to-date return, trading near its 52-week high of $420.98. According to InvestingPro data, 14 analysts have recently revised their earnings expectations upward for the upcoming period.
The price target increase reflects RBC’s view of HCA’s industry-leading margins and strong market positioning, according to the firm’s analysis.
RBC Capital cited anticipated market share gains from broader patient access as another factor supporting the higher valuation for the healthcare provider.
The firm noted a "growing likelihood of a subsidy fix" as one reason for the target increase, suggesting potential regulatory developments that could benefit HCA.
RBC also mentioned the probability of "an incremental cushion from expanded state supplemental programs in key states" as an additional factor supporting its more optimistic outlook for HCA Healthcare.
In other recent news, HCA Healthcare Inc. reported strong second-quarter results for 2025, surpassing both earnings and revenue forecasts. The company achieved earnings per share of $6.84, which was higher than the expected $6.27, representing a 9.09% surprise. Additionally, HCA’s revenue reached $18.61 billion, slightly above the anticipated $18.49 billion. Following these results, Bernstein raised its price target for HCA Healthcare from $404 to $417, although it maintained a Market Perform rating. Bernstein noted that while HCA exceeded earnings expectations with an adjusted EBITDA of $3,849 million, there was a deceleration in patient volumes. Meanwhile, Wolfe Research downgraded HCA Healthcare from Outperform to Peerperform due to concerns about potential multi-year payer mix pressure, particularly Exchange pressure in 2026 and Provider Tax pressure in 2028 and beyond. These developments highlight the mixed analyst sentiment surrounding HCA Healthcare amid its recent financial performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.